Pfizer Inc
If you can't build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies — […]
Read More
Pfizer shares fall as 2024 revenue and profit forecast disappoints
Shares of Pfizer fell Wednesday after the drugmaker forecast 2024 revenue and profit below Wall Street’s expectations, as it sees weak demand for its once-blockbuster Covid products. Pfizer also raised the target of its sweeping cost-cutting plan by $500 million, bringing the anticipated total to $4 billion. The company expects 2024 revenue of $58.5 billion […]
Read More
Inventory futures tick better as traders await Fed determination: Dwell updates
Traders function on the flooring at the New York Inventory Exchange (NYSE) in New York Metropolis, U.S., December 1, 2023. Brendan Mcdermid | Reuters U.S. inventory futures ticked better Wednesday as buyers await the Federal Reserve’s latest coverage decision. Dow Jones Industrial Average futures rose by 42 details, or .1%. S&P 500 futures acquired .1% […]
Read More
Biden administration asserts ability to seize drug patents in shift to slash significant charges
President Joe Biden speaks about guarding Social Protection, Medicare, and lowering prescription drug expenditures, during a stop by to OB Johnson Park and Local community Centre, in Hallandale Beach front, Florida, on Nov. 1, 2022. Kevin Lamarque | Reuters The Biden administration on Thursday asserted its authority to seize the patents of sure highly-priced prescription […]
Read More
Eli Lilly vs. Novo Nordisk: The professionals supply their verdict on the viral body weight-reduction stocks
It has been really a calendar year for both Eli Lilly and Novo Nordisk given the increase in excess weight-reduction drugs. Stocks of both pharmaceutical corporations have rallied this 12 months. Shares in Eli Lilly are up all over 60% yr-to-date, while its Danish counterpart Novo Nordisk has noticed a achieve of about 50%. As […]
Read More
Free ChatGPT may incorrectly answer drug questions, study says
Harun Ozalp | Anadolu | Getty Images The free version of ChatGPT may provide inaccurate or incomplete responses — or no answer at all — to questions related to medications, which could potentially endanger patients who use OpenAI’s viral chatbot, a new study released Tuesday suggests. Pharmacists at Long Island University who posed 39 questions […]
Read More
Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops
Sopa Images | Lightrocket | Getty Images Pfizer’s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients taking the drug […]
Read More
Why Pfizer’s latest stumble in the obesity market is a boon for Eli Lilly
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after patients in a mid-stage trial experienced […]
Read More
Stocks building the most significant moves midday: Tesla, Disney, Alibaba, Ulta Splendor and a lot more
Examine out the organizations creating headlines in midday trading. Tesla — Tesla shares slipped less than 1% as Wall Road assessed the firm’s extensive-anticipated Cybertruck pursuing a supply start occasion Thursday in Texas. Disney — Disney shares were being nearly flat soon after the leisure large reinstated its dividend at 30 cents per share amid […]
Read More
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The drugmaker observed high rates of adverse side effects, which were mostly mild and gastrointestinal, among patients. A significant […]
Read More